Your browser doesn't support javascript.
loading
CAS9 is a genome mutator by directly disrupting DNA-PK dependent DNA repair pathway.
Xu, Shuxiang; Kim, Jinchul; Tang, Qingshuang; Chen, Qu; Liu, Jingfeng; Xu, Yang; Fu, Xuemei.
Afiliación
  • Xu S; Cancer Research Institute, Guangdong Provincial Key Laboratory of Cancer Immunotherapy, School of Basic Medical Sciences, Southern Medical University, Guangzhou, 510515, China.
  • Kim J; The Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen, 518033, China.
  • Tang Q; Division of Biological Sciences, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA, 92093, USA.
  • Chen Q; Cancer Research Institute, Guangdong Provincial Key Laboratory of Cancer Immunotherapy, School of Basic Medical Sciences, Southern Medical University, Guangzhou, 510515, China.
  • Liu J; Cancer Research Institute, Guangdong Provincial Key Laboratory of Cancer Immunotherapy, School of Basic Medical Sciences, Southern Medical University, Guangzhou, 510515, China.
  • Xu Y; The Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen, 518033, China.
  • Fu X; Cancer Research Institute, Guangdong Provincial Key Laboratory of Cancer Immunotherapy, School of Basic Medical Sciences, Southern Medical University, Guangzhou, 510515, China.
Protein Cell ; 11(5): 352-365, 2020 05.
Article en En | MEDLINE | ID: mdl-32170574
ABSTRACT
With its high efficiency for site-specific genome editing and easy manipulation, the clustered regularly interspaced short palindromic repeats (CRISPR)/ CRISPR associated protein 9 (CAS9) system has become the most widely used gene editing technology in biomedical research. In addition, significant progress has been made for the clinical development of CRISPR/CAS9 based gene therapies of human diseases, several of which are entering clinical trials. Here we report that CAS9 protein can function as a genome mutator independent of any exogenous guide RNA (gRNA) in human cells, promoting genomic DNA double-stranded break (DSB) damage and genomic instability. CAS9 interacts with the KU86 subunit of the DNA-dependent protein kinase (DNA-PK) complex and disrupts the interaction between KU86 and its kinase subunit, leading to defective DNA-PK-dependent repair of DNA DSB damage via non-homologous end-joining (NHEJ) pathway. XCAS9 is a CAS9 variant with potentially higher fidelity and broader compatibility, and dCAS9 is a CAS9 variant without nuclease activity. We show that XCAS9 and dCAS9 also interact with KU86 and disrupt DNA DSB repair. Considering the critical roles of DNA-PK in maintaining genomic stability and the pleiotropic impact of DNA DSB damage responses on cellular proliferation and survival, our findings caution the interpretation of data involving CRISPR/CAS9-based gene editing and raise serious safety concerns of CRISPR/CAS9 system in clinical application.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Proteínas Quinasas / ADN / Reparación del ADN / Repeticiones Palindrómicas Cortas Agrupadas y Regularmente Espaciadas / Edición Génica / Proteína 9 Asociada a CRISPR Límite: Humans Idioma: En Revista: Protein Cell Asunto de la revista: BIOQUIMICA Año: 2020 Tipo del documento: Article País de afiliación: China

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Proteínas Quinasas / ADN / Reparación del ADN / Repeticiones Palindrómicas Cortas Agrupadas y Regularmente Espaciadas / Edición Génica / Proteína 9 Asociada a CRISPR Límite: Humans Idioma: En Revista: Protein Cell Asunto de la revista: BIOQUIMICA Año: 2020 Tipo del documento: Article País de afiliación: China